Therapeutic effects of Stronger Neo-Minophagen C (SNMC) in patients with chronic liver disease

To evaluate the therapeutic efficacy of Stronger Neo-Minophagen C (SNMC) in patients with chronic liver diseases, a multicenter prospective study was performed in Beijing, China. A total of 109 patients were treated with SNMC intravenous injection and SNMC tablets (Minophagen Pharmaceutical Co., Tok yo, Japan). They responded to the treatment with marked effective rate of 6 6% and overall effective rate of 75%. SNMC was shown to lower serum ALT and AST levels shortly after the administration, especially for the patients w ith higher serum levels. Serum bilirubin was reduced simultaneously, and me tabolism of protein was improved. SNMC was proved to be safe with minimal s ide effects. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.